Related Experiment Videos
The impact of gene therapy on T cell function in cancer
1Division of Clinical Immunology, Mount Sinai School of Medicine, New York, NY 10029, USA.
Abstract:
Studies of signal transduction by T cells are slowly identifying the intracellular messengers that must be generated for full T cell activation to take place. The recent, convincing identification of several tumor-associated antigens (TAA) has transformed our task into trying to define the mechanisms that underlie the failure of T cells to destroy antigenic tumor cells. Although there are a variety of hypotheses that explain why tumors grow progressively, even if they are antigenic, recent evidence suggests that T cells from tumor-bearing patients exhibit abnormalities in signal transduction that render them unable to respond to appropriate activation signals, even following proper stimulation. Gene therapy with interleukin-2 (IL-2)-secreting tumor cells in an animal model has been effective in preventing the onset of these signaling defects. Discovery of the molecular mechanisms by which such cytokine-secreting tumor cells induce immune responses and how they may best be applied clinically may provide clearer indications of the directions to pursue to alter the balance between the T cell and the tumor cell in the patient's favor.
Insights
T cells from cancer patients show signaling defects, hindering tumor destruction. Gene therapy using interleukin-2 (IL-2)-secreting tumor cells shows promise in animal models for overcoming these T cell abnormalities.
Area of Science:
- Immunology
- Cancer Biology
- Molecular Medicine
Background:
- T cell activation relies on specific intracellular signaling pathways.
- Tumor-associated antigens (TAA) are identified, yet T cells fail to eliminate antigenic tumors.
- Tumor-bearing patients' T cells exhibit signal transduction abnormalities, impairing activation.
Purpose of the Study:
- To investigate the mechanisms behind T cell dysfunction in cancer.
- To explore strategies for restoring T cell anti-tumor immunity.
- To define the clinical potential of cytokine-secreting tumor cell therapy.
Main Methods:
- Analysis of T cell signal transduction pathways in tumor-bearing patients.
- Utilizing an animal model for gene therapy with interleukin-2 (IL-2)-secreting tumor cells.
- Investigating molecular mechanisms of immune response induction by engineered tumor cells.
Main Results:
- T cells from tumor-bearing patients demonstrate impaired signal transduction.
- Gene therapy with IL-2-secreting tumor cells prevented signaling defects in an animal model.
- Evidence suggests a potential therapeutic strategy to enhance anti-tumor immunity.
Conclusions:
- T cell signaling defects contribute to tumor progression.
- Interleukin-2 (IL-2)-secreting tumor cell gene therapy offers a promising approach to restore T cell function.
- Further research into molecular mechanisms can guide clinical applications to favor the patient's immune response against cancer.